FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Ondek | drinkable vaccine | Barry Marshall
Syndicate content

Ondek plots human trials of drinkable flu vaccine

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!


Australian Nobel Prize winner Barry Marshall is planning a trial of a new drinkable flu vaccine. His company, Ondek, plans to enroll 30 subjects later this year, with results expected in 2013.

Ondek's vaccine replaces genes in the stomach bug Helicobacter pylori with those of the flu and other viruses, according to Bloomberg, with the goal of eliciting an immune response as the bug colonizes the gut. The advantage of a drinkable vaccine is that essential components can be freeze-dried, simplifying the storage and delivery of the vaccine and bypassing the possibility of injection-site reactions. Early testing of a "disarmed" version of the delivery method showed that the bug was capable of colonizing the stomach.

"We're focusing on flu because we think that would be attractive to investors," Marshall told Bloomberg. "That's the big market." Ondek's 20 investors have banded together to raise $3.1 million, though more will be needed once trials begin.

- read the Bloomberg story

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about Ondek   drinkable vaccine   Barry Marshall  


Post a comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

This question is for testing whether you are a human visitor and to prevent automated spam submissions.